missing translation for 'onlineSavingsMsg'
Learn More
Please login to your online account to display your discounted pricing

LYVE1, eFluor 570, clone: ALY7, eBioscience™

Rat Monoclonal Antibody

Manufacturer:  Life Technologies LS41044380

 View more versions of this product

Catalog No. 501128598



Description

Description

The lymphatic vasculature forms a second circulatory system that drains extracellular fluid from the tissues and provides an exclusive environment in which immune cells can encounter and respond to foreign antigen. Recently a number of interesting molecules have been identified that may be exploited as markers for lymphatic endothelium, including the hyaluronan receptor LYVE1, PALE, VEGFR3, and podoplanin. LYVE1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module, the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.

It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Filter Recommendation: When using this eFluor® 570 antibody conjugate, we recommend a filter that will capture the 570 emission wavelength (for example, Excitation 545/25, 565LP, Emission 605/70). A standard Alexa Fluor® 555 or TRITC filter is acceptable. Excitation: 555 nm; Emission: 570 nm LYVE1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluro) on the lymph vessel wall. The deduced amino acid sequence of LYVE1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module, the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves. LYVE1 is a type I integral membrane glycoprotein. LYVE-1 is expressed primarily on lymphatic vessel endothelium and is likely to be involved in regulating the traffic of leucocytes and tumor cells to lymph nodes. The lymphatic vasculature forms a second circulatory system that drains extracellular fluid from the tissues and provides an exclusive environment in which immune cells can encounter and respond to foreign antigen. A number of molecules have been identified as markers for lymphatic endothelium which include LYVE1, PALE, VEGFR3, and podoplanin. Diseases associated with LYVE1 dysfunction includes Complete Androgen Insensitivity Syndrome.
Specifications

Specifications

LYVE1
Monoclonal
0.2 mg/mL
PBS with 0.09% sodium azide; pH 7.2
Q8BHC0
Extracellular link domain containing 1, HAR, hyaluronic acid receptor, lymphatic vessel endothelial hyaluro receptor 1, LYVE-1, XLKD1
Rat
Affinity chromatography
RUO
Antibody
Monoclonal
Mouse
Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Frozen)
ALY7
eFluor® 570
Lyve1
Liquid
Lyve1
IgG1, kappa
25 μg
4° C, store in dark, DO NOT FREEZE!
Primary
114332
Documents

For Research Use Only.